113 related articles for article (PubMed ID: 11904588)
1. The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma.
Nowicki M; Adamkiewicz G; Bryc W; Kokot F
Am J Obstet Gynecol; 2002 Mar; 186(3):340-4. PubMed ID: 11904588
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum leptin levels during GnRH agonist therapy.
Douchi T; Kuwahata T; Yoshimitsu N; Iwamoto I; Yamasaki H; Nagata Y
Endocr J; 2003 Jun; 50(3):355-9. PubMed ID: 12940465
[TBL] [Abstract][Full Text] [Related]
3. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
[TBL] [Abstract][Full Text] [Related]
4. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
[TBL] [Abstract][Full Text] [Related]
7. Inverse relationship between the changes in trunk lean and fat mass during gonadotropin-releasing hormone agonist therapy.
Douchi T; Kuwahata R; Yamasaki H; Yamamoto S; Oki T; Nakae M; Nagata Y
Maturitas; 2002 May; 42(1):31-5. PubMed ID: 12020977
[TBL] [Abstract][Full Text] [Related]
8. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
9. Effects of Gn-RH, TRH, and CRF administration on plasma leptin levels in lean and obese women.
Komorowski J; Jankiewicz-Wika J; Stepień H
Neuropeptides; 2000 Apr; 34(2):89-97. PubMed ID: 10985925
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
12. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS.
Krotkiewski M; Landin K; Dahlgren E; Janson PO; Holm G
Gynecol Obstet Invest; 2003; 55(2):88-95. PubMed ID: 12771455
[TBL] [Abstract][Full Text] [Related]
13. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
15. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography.
Lee WL; Liu RS; Yuan CC; Chao HT; Wang PH
Fertil Steril; 2001 Mar; 75(3):638-9. PubMed ID: 11239559
[No Abstract] [Full Text] [Related]
16. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
17. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa.
Wang PH; Lee WL; Chao HT; Shu LP; Kao HL; Wu CW; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):294-9. PubMed ID: 10389284
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma.
Mohammed NH; Al-Taie A; Albasry Z
Int J Clin Pharm; 2020 Jun; 42(3):931-937. PubMed ID: 32350747
[TBL] [Abstract][Full Text] [Related]
19. Age, insulin, SHBG and sex steroids exert secondary influence on plasma leptin level in women.
Milewicz T; Krzysiek J; Janczak-Saif A; Sztefko K; Krzyczkowska-Sendrakowska M
Endokrynol Pol; 2005; 56(6):883-90. PubMed ID: 16821206
[TBL] [Abstract][Full Text] [Related]
20. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
